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OBSERVATIONS
HDL Dysfunctionality
(Paraoxonase) Is
Worse in
Nondiabetic,
Postmenopausal
African American
Than in White
Women
A
frican American women (AAW) suf-
fer two- to fourfold greater rates of
cardiovascular disease (CVD) mor-
tality and morbidity compared with those
in white American women (WAW). The
reasons for the higher CVD mortality in
African Americans are uncertain. It is
generally well established that HDL cho-
lesterol (HDL-C) is antiatherogenic and
cardioprotective. Indeed, several prospec-
tive studies have revealed that HDL-C
is protective of coronary heart disease.
Most of these studies were in white
populations (1). However, these HDL-C
and coronary heart disease relationships
do not appear to apply to African Ameri-
cans. Indeed, AAW have higher HDL-C
than WAW. Thus, the higher CVD in
AAW in the presence of higher HDL-C
is paradoxical and suggests that HDL is
possibly less cardioprotective in AAW.
We have postulated that in AAW, HDL
appears to be qualitatively dysfunctional
or AAW are resistant to HDL’sc a r d i o p r o -
tective effects, i.e., HDL resistance. In this
regard, previous studies have attributed
the antiatherogenic properties of HDL to
reverse cholesterol transport (2). How-
e v e r ,r e c e n te v i d e n c es u g g e s t st h a tH D L
is an antioxidant and inhibits the oxida-
tion of LDL as well as possesses anti-
inﬂammatory properties (3).
Paraoxonase (PON1) enzyme activity
is associated with HDL functionality.
Serum PON1 is coassociated with HDL
and apolipoprotein (apo) A1 (apoA1) in
the circulation. PON1 is reported to be
responsible for the antioxidant and anti-
inﬂammatory properties of HDL (4,5).
Therefore, to explore the paradox of
higher HDL-C and worse CVD mortality
and morbidity in AAW and WAW, we
examined 1) the HDL-associated PON1
enzyme activity and oxidized LDL
(ox-LDL)and2)theconcomitantsubclin-
ical proinﬂammatory markers (high-
sensitivity C-reactive protein [hsCRP]
and interleukin-6 [IL-6]) in AAW and
WAW. We studied PON1 and the CVD
risk factors in 42 nondiabetic, postmeno-
pausalAAWandWAW(meanage57.26
3.6years,BMI30.36 6.3kg/m2,systolic
bloodpressure120.76 15.5mmHg,and
diastolic blood pressure 74.3 6 7.4
mmHg). Fasting blood samples for
PON1, lipids and lipoproteins, apoAl
and apoB, and hsCRP and IL-6 were ob-
tained. Standard oral glucose tolerance
test with fasting and 2-h serum glucose,
insulin, and C-peptide was performed.
Insulin resistance was calculated by ho-
meostasis model assessment of insulin
resistance (HOMA-IR). ox-LDL was mea-
sured by enzyme-linked immunosorbent
assay.
Our AAW were more obese (BMI
32.8 6 6.5 vs. 27.8 6 5.0 kg/m
2, P 5
0.007) compared with WAW. There were
nosigniﬁcantdifferencesinfastingand2-h
glucose, insulin, C-peptide, HOMA-IR,
and blood pressure. We found no signiﬁ-
cantdifferencesintotalcholesterol,HDL-C
(58 6 16.54 vs. 55.04 6 16.97 mg/dL,
P 5 0.57), LDL-C (89.22 6 25.75 vs.
85.23 6 16.37 mg/dL, P 5 0.552), apoB,
and IL-6 in AAW and WAW. However,
wefoundsigniﬁcantly lowerserumtriglyc-
eride level (62.2 6 23.4 vs. 88.3 6 46.5
mg/dL, P 5 0.02) and higher apoA1
(185.2 6 29.7 vs. 159.7 6 46 mg/dL,
P 5 0.03) in AAW compared with
WAW. In contrast, we found signiﬁcantly
lower PON1 (0.97 6 0.35 vs. 2.09 6 0.29
ng/mL, P 5 0.0001) and higher ox-LDL
(8.2 6 2.5 vs. 4.5 6 1.6 units/L, P 5
0.001) and a tendency toward higher
hsCRP (3.96 6 3.7 vs. 2.2 6 2.5 mg/L,
P 5 0.07) in AAW than WAW.
Our pilot study demonstrates several
HDL-related functional differences in
nondiabetic postmenopausal AAW and
WAW.Despite amore favorablelipidand
lipoprotein proﬁle in AAW, we found
signiﬁcantly lower PON1 and higher ox-
LDL and hsCRP in AAW compared with
WAW. We conclude that HDL may be
dysfunctional, as measured by PON1, in
AAW compared with WAW. We specu-
late that the excess proinﬂammatory
peptides and enhanced LDL oxidation,
perhaps associated with HDL-related
dysfunction, could mediate the higher
CVD mortality and morbidity in AAW
compared with WAW. Further studies to
elucidate the ethnic HDL functionality
differences are warranted.
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